This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| gentamicin | |
|---|---|
| Name | Gentamicin |
| Routes of administration | Intravenous, intramuscular, topical, ophthalmic |
| Drug class | Aminoglycoside antibiotic |
| Legal status | Prescription-only |
| Bioavailability | Variable (poor oral) |
| Protein binding | Low |
| Metabolism | Minimal |
| Elimination half-life | ~2–3 hours (normal renal function) |
| Excretion | Renal (glomerular filtration) |
gentamicin
Gentamicin is an aminoglycoside antibiotic widely used to treat severe Gram-negative and selected Gram-positive bacterial infections. It is employed in hospital settings for life‑threatening sepsis, endocarditis, burn infections and complicated intra-abdominal and urinary tract infections, often in combination with beta‑lactam agents or glycopeptides. Clinical practice, regulatory agencies and infectious disease guidelines guide dosing, monitoring and restrictions because of the drug’s narrow therapeutic index and nephrotoxic and ototoxic potential.
Gentamicin is indicated for severe infections caused by susceptible organisms such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella species and Enterobacter species, and is used alongside agents like ceftriaxone, piperacillin/tazobactam and vancomycin in empiric regimens. In neonatal and pediatric practice gentamicin remains part of protocols endorsed by entities comparable to pediatric infectious disease societies and neonatal intensive care units for neonatal sepsis and meningitis when recommended by local antimicrobial stewardship committees. In surgical and trauma contexts it is applied for prophylaxis and treatment of infections in burn units, trauma centers and transplant programs. Ophthalmic and topical formulations are used in ophthalmology clinics, dermatology departments and wound-care services for superficial bacterial infections.
Gentamicin is a bactericidal agent that binds to the 30S ribosomal subunit, interfering with initiation complex formation and causing misreading of mRNA; this mechanism is taught in medical curricula and referenced in textbooks used at institutions such as Harvard Medical School, Johns Hopkins University and Oxford University. The drug demonstrates concentration-dependent killing and a post-antibiotic effect, concepts discussed in pharmacology texts and incorporated into dosing protocols endorsed by organizations such as the Infectious Diseases Society of America and the World Health Organization. Pharmacokinetic properties include poor oral absorption, substantial renal elimination affecting dosing in patients managed in nephrology units and critical care settings, and low protein binding. Therapeutic drug monitoring is standard in intensive care and transplant centers, guided by clinical laboratory standards from bodies like the Clinical and Laboratory Standards Institute and national drug regulatory agencies.
Well-documented adverse effects include nephrotoxicity and ototoxicity, which have implications for nephrology clinics, audiology services, and long-term care facilities. Nephrotoxicity typically manifests as acute tubular necrosis with rising creatinine levels, prompting input from nephrologists and hospital pharmacists. Ototoxicity can present as vestibular dysfunction or irreversible sensorineural hearing loss, leading to collaboration with otolaryngology and audiology departments for baseline and follow-up audiometry. Other safety considerations include neuromuscular blockade in perioperative settings involving anesthesiology teams and electrolyte disturbances managed by clinical chemistry laboratories. Risk factors acknowledged in clinical guidelines include concomitant use of loop diuretics, prolonged courses as encountered in chronic wound clinics, and impaired renal function often managed by renal transplant services.
Bacterial resistance to aminoglycosides is mediated by enzymatic modification (aminoglycoside-modifying enzymes), ribosomal target alteration and reduced uptake or increased efflux, phenomena studied in microbiology departments and described in reviews from research centers at institutions such as the Pasteur Institute and the Max Planck Society. Plasmid-borne resistance determinants have been identified in hospital outbreaks investigated by infection control teams and public health agencies including national Centers for Disease Control. Surveillance networks and academic consortia publish susceptibility trends that inform empiric therapy in tertiary hospitals and influence stewardship programs at universities like Stanford and Cambridge.
Gentamicin is available for parenteral administration as intravenous and intramuscular formulations used in emergency departments, operating rooms and inpatient wards; topical and ophthalmic preparations are used in outpatient clinics and specialty practices. Dosing strategies include traditional multiple-daily dosing and extended-interval once-daily dosing, approaches evaluated in randomized trials conducted at medical centers such as Mount Sinai and Karolinska University Hospital. Therapeutic drug monitoring—peak and trough concentrations—is routinely performed in hospital laboratories to optimize efficacy and reduce toxicity, with dose adjustments recommended by clinical pharmacists and infectious disease consultants.
Aminoglycoside antibiotics emerged from mid-20th century antibiotic discovery efforts led by researchers affiliated with institutions such as the University of Wisconsin and pharmaceutical companies of the era. Gentamicin itself was characterized and developed in the context of antibiotic research programs contemporaneous with the discovery of streptomycin and neomycin, and its clinical adoption followed regulatory review by national agencies analogous to the United States Food and Drug Administration and the European Medicines Agency. Historical use expanded through the latter half of the 20th century as hospitals, military medical units and public health systems incorporated gentamicin into formularies for management of severe Gram-negative infections.
Gentamicin’s role in modern healthcare intersects with antimicrobial stewardship campaigns, hospital formulary decisions and global public health initiatives addressing antimicrobial resistance coordinated by organizations such as the World Health Organization and national public health institutes. Its inclusion on essential medicines lists maintained by international bodies informs procurement and guideline development in low- and middle-income countries, influencing practice in tertiary referral hospitals and community health centers. Debates involving patient safety advocates, professional societies in nephrology and otolaryngology, and regulatory authorities shape policies on monitoring, label warnings and restricted use in ambulatory versus inpatient settings.
Category:Antibiotics